Skip to main content

Breast Cancer News

News
02/02/2023
Maria Asimopoulos
Using data from more than 500,000 women treated in Veterans Affairs facilities, researchers evaluated associations between breast cancer diagnoses and history of deployment.
Using data from more than 500,000 women treated in Veterans Affairs facilities, researchers evaluated associations between breast cancer diagnoses and history of deployment.
Using data from more than...
02/02/2023
Veterans Health Today
News
12/05/2019
The use of intensity modulated radiation therapy after lumpectomy in early-stage breast cancer is associated with roughly $8500 more in Medicare expenditures yet yields no expected major clinical benefit.
The use of intensity modulated radiation therapy after lumpectomy in early-stage breast cancer is associated with roughly $8500 more in Medicare expenditures yet yields no expected major clinical benefit.
The use of intensity modulated...
12/05/2019
First Report Managed Care
News
11/13/2019
“This suggests that some of the economies of scale, access to capital, and care delivery efficiencies gained from increased market power following hospital mergers are passed onto payers and consumers as lower costs,” researchers wrote.
“This suggests that some of the economies of scale, access to capital, and care delivery efficiencies gained from increased market power following hospital mergers are passed onto payers and consumers as lower costs,” researchers wrote.
“This suggests that some of the...
11/13/2019
First Report Managed Care
News
11/06/2019
“Ongoing monitoring of incentive programs is critical to determining the effectiveness of financial incentives and their effects on the improvement of cancer screening delivery rates,” researchers wrote.
“Ongoing monitoring of incentive programs is critical to determining the effectiveness of financial incentives and their effects on the improvement of cancer screening delivery rates,” researchers wrote.
“Ongoing monitoring of incentive...
11/06/2019
First Report Managed Care
News
10/15/2019
Researchers recently found that unselected genetic testing of all women following breast cancer diagnosis appears highly cost-effective compared with the standard practice of testing select women based on clinical criteria or family history.
Researchers recently found that unselected genetic testing of all women following breast cancer diagnosis appears highly cost-effective compared with the standard practice of testing select women based on clinical criteria or family history.
Researchers recently found that...
10/15/2019
First Report Managed Care
News
10/09/2019
“The data obtained in our study quantify the economic value of delaying or preventing disease progression and may inform payers and physician groups about value-based payment programs,” researchers wrote.
“The data obtained in our study quantify the economic value of delaying or preventing disease progression and may inform payers and physician groups about value-based payment programs,” researchers wrote.
“The data obtained in our study...
10/09/2019
First Report Managed Care
News
05/23/2018
In a Managed Care Learning Network session, Adam M Brufsky, MD, PhD, and Edward Li, PharmD, MPH, outlined the clinical and cost implications of HER2+ breast cancer treatment in the era of biosimilars, clinical pathways, and precision...
In a Managed Care Learning Network session, Adam M Brufsky, MD, PhD, and Edward Li, PharmD, MPH, outlined the clinical and cost implications of HER2+ breast cancer treatment in the era of biosimilars, clinical pathways, and precision...
In a Managed Care Learning...
05/23/2018
First Report Managed Care
News
11/30/2016
Pfizer recently announced its drug PF-05280014, biosimilar of Herceptin (trastuzumab; Roche Holding AG), met its main goal in a key study for breast cancer treatment.
Pfizer recently announced its drug PF-05280014, biosimilar of Herceptin (trastuzumab; Roche Holding AG), met its main goal in a key study for breast cancer treatment.
Pfizer recently announced its...
11/30/2016
First Report Managed Care
News
11/21/2016
Recent data suggests that Ibrance (palbociclib; Pfizer) combined with letrozole nearly doubles progression-free survival in women with advanced estrogen-receptor (ER)-positive, HER2-negative breast cancer, compared with letrozole alone.
Recent data suggests that Ibrance (palbociclib; Pfizer) combined with letrozole nearly doubles progression-free survival in women with advanced estrogen-receptor (ER)-positive, HER2-negative breast cancer, compared with letrozole alone.
Recent data suggests that...
11/21/2016
First Report Managed Care
News
10/25/2016
According to a study, bundled payments based on pay-for-performance for breast cancer treatment may lead to better adherence, improved outcomes, and reduced costs.
According to a study, bundled payments based on pay-for-performance for breast cancer treatment may lead to better adherence, improved outcomes, and reduced costs.
According to a study, bundled...
10/25/2016
First Report Managed Care